Thrivent Financial for Lutherans Boosts Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Thrivent Financial for Lutherans lifted its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 8.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 77,941 shares of the medical device company’s stock after purchasing an additional 5,940 shares during the period. Thrivent Financial for Lutherans’ holdings in Cooper Companies were worth $7,165,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in COO. Byrne Asset Management LLC acquired a new stake in Cooper Companies in the 4th quarter valued at about $33,000. OFI Invest Asset Management acquired a new stake in Cooper Companies in the fourth quarter valued at approximately $34,000. Brown Brothers Harriman & Co. lifted its stake in Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares during the last quarter. West Financial Advisors LLC acquired a new position in Cooper Companies during the 4th quarter worth approximately $49,000. Finally, Atala Financial Inc acquired a new position in Cooper Companies during the 4th quarter worth approximately $51,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Stock Up 1.6 %

Shares of NASDAQ COO opened at $81.71 on Monday. The business has a 50-day moving average price of $90.05 and a 200 day moving average price of $98.04. The stock has a market cap of $16.34 billion, a PE ratio of 41.90, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The Cooper Companies, Inc. has a 52-week low of $77.05 and a 52-week high of $112.38.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. Equities research analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on COO. StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Morgan Stanley cut their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Citigroup lowered their price objective on Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Robert W. Baird cut their target price on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th. Finally, Piper Sandler restated an “overweight” rating and set a $115.00 target price (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.25.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.